Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

The number of new cases of cutaneous B-cell lymphoma has leveled off since the early 2000s, and survival rates have improved since 1973.

This study found that patients receiving immune checkpoint inhibitors who have a history of psoriasis are at a higher risk for developing gastrointestinal and endocrine toxicities within one year compared to those without psoriasis.

This study reported that intensive immunosuppression in multiple sclerosis patients significantly reduced relapse rates versus pre-treatment expectations, though some required ongoing treatment after tapering.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study demonstrated that CD19-CAR T cell therapy may promote structural regeneration in the skin of systemic sclerosis patients, as evidenced by histological improvements and fibroblast population changes, suggesting its potential for tissue remodeling in fibrotic diseases.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

This study found that combining intralesional PTX and corticosteroids may enhance treatment outcomes for alopecia areata, with PTX showing better long-term effects compared to corticosteroids alone.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

In this study, PEVIII, a nanocomposite chitosan-coated vesicle containing both α-hederin and hederacoside C, demonstrated notable antibacterial activity against Pseudomonas aeruginosa in a keratitis model, showing significant lesion reduction, tissue improvement, and decreased bacterial load and inflammatory markers compared to other treatments.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This study found that a nano-cubosome formulation co-loaded with capsaicin and thiocolchicoside enhanced bioavailability and showed promising analgesic and anti-inflammatory effects in rats, potentially benefiting gout management through improved transdermal delivery.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

Early sunburn treatment with certain inhibitors may reduce skin cancer risk.

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.

Enhancing Tregs can protect against alopecia areata.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

In this study, researchers described ONCO-NK-TRANSITION-GM1, a cancer therapy that's manufacturable with current pharmaceutical methods, showing a 60-80% complete response rate across various cancer types and costing $50 per dose, providing a more accessible alternative to existing treatments.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

This study found that the meropenem-loaded spanlastic formulation showed strong potential as an effective topical therapy for bacterial skin infections in non-diabetic mice, demonstrating superior therapeutic activity and wound healing compared to free meropenem.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

This study found that combining intra-arterial chemotherapy with Traditional Chinese Medicine may improve response rates in malignant bone and soft tissue tumor treatment while also managing specific side effects.

This case report describes a woman diagnosed with Cronkhite-Canada syndrome whose gastrointestinal symptoms and alopecia improved significantly after systemic prednisone treatment, with no recurrence four years after a second treatment course.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This article reviews adverse skin reactions caused by chemotherapy and cytokine treatments, describing specific and nonspecific reactions, but reports no new clinical findings.